Fertility and Sterility, 76(5), 1057-1059
To determine the metabolic and reproductive effectiveness of rosiglitazone in polycystic ovary syndrome (PCOS).
Case report.
Academic clinical practice and General Clinical Research Center.
PATIENT(S): A 25-year-old woman with PCOS.
INTERVENTION(S): Rosiglitazone maleate, 4 mg daily for 5 months until conception.
MAIN OUTCOME MEASURE(S): Insulin sensitivity by steady-state plasma glucose technique; serum androgens, progesterone, and hCG; and pelvic ultrasound images.
RESULT(S): Rosiglitazone treatment for 5 months improved insulin sensitivity, lowered serum free testosterone, and resulted in spontaneous ovulation and conception.
CONCLUSION(S): Rosiglitazone is a promising insulin sensitizer for treatment of PCOS. Clinical trials are warranted.
Cataldo, N. A., Abbasi, F., McLaughlin, T. L., Lamendola, C., & Reaven, G. M. (2001). Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone. *Fertility and sterility*, *76*(5), 1057-1059. https://doi.org/10.1016/s0015-0282(01)02843-6
Cataldo NA, Abbasi F, McLaughlin TL, Lamendola C, Reaven GM. Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone. Fertil Steril. 2001;76(5):1057-1059. doi:10.1016/s0015-0282(01)02843-6
Cataldo, Nicholas A., et al. "Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone." *Fertility and sterility*, vol. 76, no. 5, 2001, pp. 1057-1059.
Adult, Female, Humans, Hypoglycemic Agents/therapeutic Use, Insulin/physiology, Ovulation, Polycystic Ovary Syndrome/drug Therapy/physiopathology, Pregnancy, Rosiglitazone, Thiazoles/therapeutic Use, Thiazolidinediones, Hypoglycemic Agents, Insulin, Thiazoles, Thiazolidinediones, Rosiglitazone